Karissa

Ethinylestradiol / Gestodene, the active ingredient in Karissa, is a combined oral contraceptive presented as an oral tablet for oral use. It provides hormonal contraception by preventing ovulation and is indicated for women of reproductive age seeking reliable birth control and can be used as part of a comprehensive family planning program.

GNH USA supplies Karissa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products for global reproductive health markets. The company adheres to EU GMP standards and provides regulatory support for importers.

Karissa, a combined oral contraceptive, is used to prevent pregnancy by modulating the hormonal regulation of the menstrual cycle. - Contraception: Prevents unintended pregnancy in women of childbearing potential. - Family planning: Provides reliable hormonal birth control as part of family planning strategies. - Cycle control: Helps achieve more predictable menstrual bleeding patterns. - Prevention of pregnancy: Offers a reversible method for women seeking to avoid conception.

Karissa may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of the breasts. - Headache: occasional throbbing or tension‑type pain. - Spotting: irregular light bleeding between periods. - Mood changes: irritability or mild depressive symptoms. - Weight gain: slight increase in body weight due to fluid retention.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Arterial thrombosis: stroke or myocardial infarction. - Hypertension: new‑onset or worsening high blood pressure. - Liver tumor: benign hepatic adenoma. - Severe allergic reaction: anaphylaxis or angioedema. - Visual disturbances: sudden loss of vision or eye pain.

Before prescribing Karissa, clinicians should evaluate individual risk factors and counsel patients on safe use. - Assess cardiovascular risk: review history of thromboembolic events, smoking, and hypertension. - Evaluate hepatic function: avoid use in severe liver disease. - Screen for hormone‑sensitive cancers: contraindicated in active breast or endometrial cancer. - Counsel on missed doses: provide guidance on backup contraception. - Monitor blood pressure: check regularly during treatment. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Karissa can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce contraceptive efficacy. - Other estrogen‑containing products (e.g., hormone replacement therapy): increase estrogen exposure and risk of thromboembolism. - Antiretroviral protease inhibitors (e.g., ritonavir): may affect hormone levels.

Moderate Interactions (Monitor Closely): - Antifungals such as ketoconazole: may increase plasma concentrations of gestodene. - Certain antibiotics (e.g., ampicillin, tetracycline): may slightly diminish contraceptive effect. - St. John’s wort: may modestly reduce effectiveness, requiring additional contraceptive measures.